大动脉狭窄的降脂疗法:一种药物向的门德尔式随机化研究
Jonathan L Ciofani1,2,3, Daniel Han4, Karan Rao1,2
1Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia.
European heart journal. Cardiovascular pharmacotherapy
|November 29, 2024
概括
遗传分析表明,降脂疗法,包括PCSK9抑制剂和APOC3抑制剂,显著降低大动脉狭窄症 (AS) 的风险. 这些发现支持进一步进行AS预防和治疗的临床试验.
科学领域:
- 心血管遗传学 心血管遗传学
- 药物基因组学 药物基因组学
- 翻译医学是一种翻译医学.
背景情况:
- 增加的LDL胆固醇 (LDL-c) 和甘油三 (TG) 与大动脉狭窄 (AS) 风险有关.
- 统计剂的随机试验没有显示对AS的益处,这对降脂疗法产生了不确定性.
- 药物向的门德尔随机化 (MR) 方法被用于调查降脂疗法对AS风险的遗传预测效应.
研究的目的:
- 研究降脂疗法对大动脉狭窄症 (AS) 风险的基因预测效应.
- 通过遗传代理来评估各种脂质调节药物在预防或治疗AS方面的潜力.
主要方法:
- 利用来自欧洲大型队列的全基因组关联研究 (GWAS) 总结统计数据.
- 已经确定了针对PCSK9,HMGCR,ACLY,NPC1L1,PPARA,APOC3和ANGPTL3.3的降脂剂的遗传代理.
- 采用逆方差加权 (IVW) 作为主要分析,敏感性分析包括MR-Egger和MR-PRESSO.
主要成果:
- 基因代理的PCSK9抑制与降低AS风险 (OR0.61) 有显著的关联.
- 埃泽蒂米布和贝佩多酸也显示出与降低AS风险的显著关联.
- APOC3抑制与AS风险降低有关 (OR0.78),而纤维酸和ANGPTL3抑制剂没有显著的关联.
结论:
- 基因预测的降脂疗法与AS风险降低显著相关.
- 早期和持续使用这些疗法可以防止AS的进展.
- 需要进一步的临床试验研究来证实这些发现.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
536
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
536
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
455
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455
01:23Antihypertensive Drugs: Vasodilators
479
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
479
01:25Antihypertensive Drugs: Direct Renin Inhibitors
493
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
493
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590